Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
What is the preferred concurrent chemotherapy regimen for limited stage small cell lung cancer with severe reaction to etoposide?
Related Questions
How would you approach a patient with limited stage SCLC who progressed immediately after completing chemoradiation with brain metastasis?
How do you schedule IV/PO Dexamethasone if giving immunotherapy concurrently with chemotherapy in patients with NSCLC?
What is the role for molecular agents alone for medically inoperable NSCLC who is not a good candidate for chemoRT?
Is there a role for surgical debulking for patients with stage IV lung sarcomatoid carcinoma?
How often, if ever, do patients with initially negative targetable mutation workup become positive later in recurrent lung cancer?
How does the presence of both T790M and L858R EGFR mutations impact the prognosis and management of a patient with previously untreated locally advanced adenocarcinoma of the lung?
Would you consider using IO alone for lung cancer patients who are PDL1 <1 but have high TMB?
Would you consider omission of PORT for node+ NSCLC with a positive margin in the setting of a high tumor PD-L1 score and plans for immunotherapy?
In cases where EGFR NSCLC has transformed into small-cell lung cancer after treatment with Osimertinib, and with no CNS involvement, is it advisable to continue osimertinib alongside chemotherapy?
What are your top takeaways from ESMO 2023?
